Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun;13(6):3003-3008.
doi: 10.3892/etm.2017.4368. Epub 2017 Apr 20.

Di-Huang-Yi-Zhi herbal formula attenuates amyloid-β-induced neurotoxicity in PC12 cells

Affiliations

Di-Huang-Yi-Zhi herbal formula attenuates amyloid-β-induced neurotoxicity in PC12 cells

Hong-Mei An et al. Exp Ther Med. 2017 Jun.

Abstract

Traditional Chinese medicine can be used for Alzheimer's disease management, such as the modern herbal formula Di-Huang-Yi-Zhi (DHYZ). In the present study, neuronal differentiated PC12 cells were used as a model to evaluate the effects of DHYZ against amyloid-β peptide 25-35 (Aβ25-35) induced neurotoxicity, particularly regarding cell proliferation, apoptosis and related events. Following treatment with DHYZ, cell viability, cell membrane damage, apoptosis, mitochondrial membrane potential, cytochrome c release, caspase-3 activity and levels of reactive oxygen species in PC12 cells were detected. The results demonstrated that pretreatment with DHYZ significantly protected PC12 cells from Aβ25-35-induced proliferation inhibition, lactate dehydrogenase release and apoptosis, as well as upregulating mitochondrial membrane potential and downregulating cytochrome c release and caspase-3 activation. DHYZ also inhibited the Aβ25-35-induced reactive oxygen species generation in PC12 cells. These observations suggest that DHYZ protected PC12 cells from the Aβ-induced neurotoxicity.

Keywords: Di-Huang-Yi-Zhi; PC12 cells; amyloid-β; apoptosis; mitochondria; reactive oxygen species.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Effect of DHYZ on the cell viability in Aβ-treated PC12 cells. Differentiated PC12 cells were pretreated with different concentrations of DHYZ for 1 h, followed by Aβ25–35 treatment for 24 h. Cell viability was evaluated by CCK-8 assay. Data shown are representative of three independent experiments. #P<0.01, vs. non-treated group; **P<0.01 vs. Aβ25–35 group. DHYZ, Di-Huang-Yi-Zhi; Aβ, amyloid-β; CCK-8, cell counting kit-8.
Figure 2.
Figure 2.
Effect of DHYZ on the LDH release in Aβ-treated PC12 cells. Differentiated PC12 cells were pretreated with different concentrations of DHYZ for 1 h, followed by Aβ25–35 treatment for 24 h. LDH release was determined by an LDH Cytotoxicity Assay kit, and is expressed as the fold of the control. Data are from three independent experiments. #P<0.01 vs. non-treated group; *P<0.05 and **P<0.01 vs. Aβ25–35 group. DHYZ, Di-Huang-Yi-Zhi; Aβ, amyloid-β; LDH, lactate dehydrogenase.
Figure 3.
Figure 3.
Effect of DHYZ on Aβ-induced apoptosis in PC12 cells. Differentiated PC12 cells were pretreated with different concentrations of DHYZ for 1 h, followed by Aβ25–35 treatment for 24 h. Cell death was detected by ELISA. Results are expressed the as fold of the non-treated control, and were obtained from three separate experiments. #P<0.01 vs. non-treated group; *P<0.05 and **P<0.01, vs. Aβ25–35 group. DHYZ, Di-Huang-Yi-Zhi; Aβ, amyloid-β.
Figure 4.
Figure 4.
Effect of DHYZ on Aβ-induced MMP change in PC12 cells. Differentiated PC12 cells were pretreated with different concentrations of DHYZ for 1 h, followed by Aβ25–35 treatment for 24 h. MMP was detected by JC-1 staining, and observed under a fluorescence microscope (magnification, ×200). DHYZ, Di-Huang-Yi-Zhi; Aβ, amyloid-β; MMP, mitochondrial membrane potential.
Figure 5.
Figure 5.
Effect of DHYZ on Aβ-elicited Cyt-C release in PC12 cells. Differentiated PC12 cells were pre-incubated with different concentrations of DHYZ for 1 h, followed by Aβ25–35 treatment for 24 h. Cyt-C concentration in the cytosol was determined by ELISA. Data are presented from three separate experiments. #P<0.01 vs. non-treated group; **P<0.01 vs. Aβ25–35 group. DHYZ, Di-Huang-Yi-Zhi; Aβ, amyloid-β; Cyt-C, cytochrome c.
Figure 6.
Figure 6.
Effect of DHYZ on caspase-3 activity in Aβ25–35-treated PC12 cells. Differentiated PC12 cells were pretreated with different concentrations of DHYZ for 1 h, followed by Aβ25–35 treatment for 24 h. Caspase-3 activity was detected using a kit, and is expressed as the fold of the control. Data shown are representative of three independent experiments. #P<0.01 vs. non-treated group; **P<0.01 vs. Aβ25–35 group. DHYZ, Di-Huang-Yi-Zhi; Aβ, amyloid-β.
Figure 7.
Figure 7.
Effect of DHYZ on Aβ25–35-induced ROS generation in PC12 cells. Differentiated PC12 cells were pretreated with different concentrations of DHYZ for 1 h, followed by Aβ25–35 treatment for 24 h. The production of intracellular ROS was detected by DCFH-DA staining and quantified with a fluorescence microplate reader (excitation wavelength, 488 nm; emission wavelength, 525 nm). ROS production was expressed as the fold of the control group. Data shown are representative of three independent experiments. #P<0.01 vs. non-treated group; *P<0.05 and **P<0.01, vs. Aβ25–35 group. DHYZ, Di-Huang-Yi-Zhi; Aβ, amyloid-β; ROS, reactive oxygen species; DCFH-DA, 2′,7′-dichlorofluorescin diacetate.

Similar articles

Cited by

References

    1. Masters CL, Selkoe DJ. Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2:a006262. doi: 10.1101/cshperspect.a006262. - DOI - PMC - PubMed
    1. Butterfield DA, Swomley AM, Sultana R. Amyloid β-peptide (1–42)-induced oxidative stress in Alzheimer disease: Importance in disease pathogenesis and progression. Antioxid Redox Signal. 2013;19:823–835. doi: 10.1089/ars.2012.5027. - DOI - PMC - PubMed
    1. Tayeb HO, Yang HD, Price BH, Tarazi FI. Pharmacotherapies for Alzheimer's disease: Beyond cholinesterase inhibitors. Pharmacol Ther. 2012;134:8–25. doi: 10.1016/j.pharmthera.2011.12.002. - DOI - PubMed
    1. Yu L, Lin SM, Zhou RQ, Tang WJ, Huang PX, Dong Y, Wang J, Yu ZH, Chen JL, Wei L, et al. Chinese herbal medicine for patients with mild to moderate Alzheimer disease based on syndrome differentiation: A randomized controlled trial. Zhong Xi Yi Jie He Xue Bao. 2012;10:766–776. doi: 10.3736/jcim20120707. (In Chinese) - DOI - PubMed
    1. Zhang YX, Zhang YL, Lu Y. Systematic review of randomized controlled trials of traditional Chinese medicine in treating Alzheimer's disease. Chin J Trad Chin Med Pharm. 2012;27:105–109.